Comparative Pharmacology
Head-to-head clinical analysis: AMBENYL versus PROVAL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBENYL versus PROVAL 3.
AMBENYL vs PROVAL #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
Each 5 mL contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL per day.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
None Documented
None Documented
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Category C
Category C
Antitussive/Antihistamine Combination
Antitussive